For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Edwards Lifesciences Corporation (EW) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -18 (−100…+100 Quality+Value blend) · Quality 46 · Value -71 · Sentiment 31 (timing only, not weighted) · Composite fair value $31.26 vs $90.81 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Edwards Lifesciences Corporation
EW NYSEEdwards Lifesciences Corporation is a medical technology company focused on structural heart disease and advanced cardiovascular care. The company develops and markets transcatheter heart valve replacement systems, surgical heart valves, and repair technologies used in procedures for aortic, mitral, and tricuspid valve conditions. Its portfolio also includes hemodynamic monitoring solutions that help clinicians assess cardiovascular function in hospital settings. Edwards Lifesciences serves hospitals, cardiac specialists, and healthcare systems across major global markets, with products designed for both minimally invasive and surgical applications. Headquartered in Irvine, California, Edwards Lifesciences plays a significant role in the cardiovascular device market through specialized therapies and diagnostic tools used in the treatment of complex heart disease.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 1.83
Total Equity: $10.34B
Shares: 585,800,000
Total Debt: $598.30M
Cash: $2.94B
EBITDA: $1.42B
Total Debt: $598.30M
Cash: $2.94B
Revenue: $6.07B
Revenue: $6.07B
Revenue: $6.07B
Total Equity: $10.34B
Tax Rate: 17.0%
Equity: $10.34B
Total Debt: $598.30M
Cash: $2.94B
Current Liabilities: $1.81B
Long-Term Debt: $598.30M
Total Debt: $598.30M
Total Equity: $10.34B
Shares: 585,800,000
Shares: 585,800,000
CapEx: -$260.20M
Shares: 585,800,000
Stock Price: $90.83
Net Income: $1.07B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 18, 2026 12:39am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $5.4B | $6.0B | $5.4B | $6.1B |
| Cost of Revenue | $1.2B | $1.1B | $1.4B | $1.1B | $1.3B |
| Gross Profit | $4.0B | $4.3B | $4.6B | $4.3B | $4.7B |
| Operating Expenses | $2.3B | $2.6B | $3.1B | $2.9B | $3.5B |
| Operating Income | $1.7B | $1.7B | $1.5B | $1.4B | $1.3B |
| Net Income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| EBITDA | $1.8B | $1.9B | $1.7B | $1.5B | $1.4B |
| EPS | $2.41 | $2.46 | $2.31 | $6.98 | $1.84 |
| EPS (Diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
Balance Sheet (Annual)
Last updated: Aug 18, 2026 12:19am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $862.8M | $769.0M | $1.1B | $3.0B | $2.9B |
| Total Current Assets | $3.2B | $3.1B | $4.0B | $6.3B | $6.7B |
| Total Assets | $8.5B | $8.3B | $9.4B | $13.1B | $13.7B |
| Current Liabilities | $1.0B | $1.0B | $1.2B | $1.5B | $1.8B |
| Long-Term Debt | $595.7M | $596.3M | $597.0M | $597.7M | $598.3M |
| Total Liabilities | $2.7B | $2.5B | $2.6B | $3.0B | $3.4B |
| Total Equity | $5.8B | $5.8B | $6.7B | $10.1B | $10.3B |
| Retained Earnings | $6.1B | $7.6B | $9.0B | $13.2B | $14.2B |
Cash Flow (Annual)
Last updated: Aug 18, 2026 12:39am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.7B | $1.2B | $895.8M | $542.3M | $1.6B |
| Capital Expenditure | -$325.8M | -$244.6M | -$253.0M | -$252.4M | -$260.2M |
| Free Cash Flow | $1.4B | $973.6M | $642.8M | $289.9M | $1.3B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $5.2M | $0 | $0 | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$512.8M | -$1.7B | -$879.6M | -$1.2B | -$893.4M |
| Net Change in Cash | -$332.8M | -$94.8M | $375.4M | $1.9B | -$119.3M |
Growth Trends (YoY %)
Last updated: Aug 18, 2026 12:39am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +2.9% | +11.6% | -9.4% | +11.5% |
| Gross Profit Growth | +8.0% | +7.5% | -6.6% | +9.5% |
| Operating Income Growth | +3.4% | -12.3% | -10.1% | -8.3% |
| Net Income Growth | +1.3% | -7.9% | +197.7% | -74.3% |
| EBITDA Growth | +3.5% | -11.1% | -8.6% | -7.4% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:51Even the bull case prices 64% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 84%.
| Case | Growth | Margin | Fair value | vs price ($90.81) |
|---|---|---|---|---|
| Bull — recovery | +17% | 17.7% | $32.84 | -64% |
| Base — stabilizes | +11% | 15.4% | $24.39 | -73% |
| Bear — keeps slipping | +6% | 13.1% | $17.73 | -80% |
| Stress — last quarter repeats | +13% | 7.7% | $14.30 | -84% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-18AI-read echocardiography and EHR-mining algorithms find the large undiagnosed/untreated severe aortic stenosis and tricuspid regurgitation population; Edwards' binding constraint has always been diagnosis-and-referral, not device supply, so automated screening converts directly into procedure volume on installed SAPIEN/EVOQUE capacity.
The same intelligence arms payer and health-system utilization management: AI-driven prior authorization, appropriateness scoring and site-of-service steering can slow or reprice high-cost structural heart procedures, and AI-assisted trial design/engineering modestly shortens the iteration cycle for Medtronic, Abbott and Boston Scientific rivals.
Whether AI screening tools become standard-of-care throughput in echo labs and actually convert to treated volume — observable in structural heart referral/screening-program disclosures and TAVR/TTVR procedure growth reaccelerating versus the current deceleration narrative.
Decades of randomized PMA-grade outcomes data (PARTNER), FDA/CE approvals, tissue-valve manufacturing craft and yield, physician proctoring relationships, and clinical specialists physically embedded in cath labs — none of which cheap software reproduces.
AI Lens thesis
Edwards sells a physical implant placed by a trained interventionalist under regulatory and liability constraint, so AI cannot substitute the product or the procedure; the transmission runs almost entirely through the demand funnel and the cost of evidence generation. On the demand side, algorithmic echo interpretation and EHR phenotyping attack the documented undertreatment gap that caps TAVR/TTVR TAM — a volume tailwind Edwards captures without changing its monetized unit (per-valve ASP). On the supply side, AI compresses trial simulation, imaging-based patient selection and regulatory documentation cost, relevant given operating margin has fallen from 32% to 21% on mitral/tricuspid investment. Against that, AI already sits inside the hemodynamic monitoring franchise (predictive hypotension algorithms), which is the one line where software-native entrants could commoditize the value; and payer-side AI is a genuine, underappreciated brake on reimbursed procedure counts. Net: modest positive, low magnitude, and the finding is that exposure is low rather than that AI transforms the business.
What the market may be underestimating
Upside Hemodynamic monitoring's predictive algorithms can migrate from a niche OR product into a recurring, software-priced perioperative standard — a higher-margin, non-implant revenue unit the market values as legacy hardware.
Downside AI-assisted engineering and synthetic-control trial methods lower the cost for well-capitalized rivals to close the clinical-evidence gap faster than the 5-10 year lag Edwards' moat has historically assumed, accelerating ASP erosion in aortic just as mitral/tricuspid spend peaks.
Outcome range spread 34
Growth Outlook
Analyzed 2026-08-18 00:48The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw quarterly cadence first: revenue went $1.35B → $1.41B → $1.53B → $1.55B → $1.57B → $1.65B → $1.74B over eight quarters. That's not "decelerating" — that's clean acceleration, roughly 29% cumulative over two years and ~12% YoY in the most recent print. The synthesis engine calling revenue "volatile and unreliable" is wrong on the top line; what's volatile is *net income*, which swung from $3.07B (Q3'24, clearly a Critical Care divestiture gain) to $91M (Q4'25, likely charges) to $381M to $242M. Strip the one-time items and Edwards is generating roughly $1.1-1.3B in normalized annual earnings on $6.5B run-rate revenue — that's an ~18% net margin, not the collapsing franchise the bear narrative implies. Gross margin at 78% is intact. The FCF CAGR of 44% is partly noise from a low base year, but $1.34B FCF on a $52B cap = 2.6% FCF yield, which is where the valuation debate actually lives.
Where I diverge from the synthesis: a $31 fair value on a company generating $1.34B FCF, growing revenue double-digits, with 78% gross margins and $2.34B net cash is not credible. That implies ~23x FCF as fair, which is what you'd pay for a no-growth industrial, not a category-leading medtech franchise. The market's 50x P/E is rich, sure, but P/E is distorted here by the divestiture-noisy denominator; on EV/EBITDA of 35x and EV/Sales of 8.2x, Edwards trades at a premium to Medtronic (~15x EBITDA) and Boston Scientific (~28x) but that gap has historically existed and TMTT (PASCAL, EVOQUE) is a real second act — not vaporware. The thesis-eval claim that price embeds "56% FCF growth for 5 years" is arithmetically aggressive; a more defensible reverse-DCF at 9% WACC and 3% terminal gets you to roughly 10-12% FCF CAGR needed, which is demanding but not fantasy given the recent revenue trajectory.
That said, the contrarian bear case has teeth the models underweight. Operating income declined from $1.75B (2022) to $1.26B (2025) despite revenue growing — that's real operating deleverage, likely from TMTT investment and pricing pressure in mature TAVR. ROE dropped to 10.4% from historically high-teens. Insider activity is uniformly one-sided: every non-award transaction is a sale, including same-day option-exercise-and-dump patterns — that's not "neutral," that's insiders taking chips off the table at $90+. Boston Scientific's Acurate neo2 and Abbott's Navitor are gaining European share, and US TAVR volume growth is decelerating from the 15%+ era to high single digits. If TMTT doesn't inflect to $1B+ revenue by 2027, the multiple compresses regardless of narrative.
Net: I partially dissent from the synthesis. The composite $31 fair value is a modeling artifact — probably driven by treating the divestiture-distorted 2024 earnings as a normalized base or by punitive growth haircuts. Edwards is overvalued, but fair value is closer to $65-72 (roughly 20-22x normalized $2.50-2.80 EPS, or ~28x $1.5B forward FCF), not $31. At $90.83 that's still ~25-30% downside, and the insider selling + operating margin compression argue against catching it here. I'd want to see either (a) TMTT quarterly revenue exceeding $150M with expanding contribution margin, or (b) the stock in the low $70s before committing. The market-forces "neutral" call and the narrative layer's "moderate durability" read are closest to right; the synthesis is directionally correct but numerically overwrought.
GPT Reading
At $90.83, Edwards is being valued like a premium growth med-tech compounder, but the financials in front of us look much more like a very good franchise going through an earnings reset. The cleanest way to see it is the mismatch between scale, growth, and price: 2025 revenue was $6.07B, up about 12% from $5.44B in 2024, and the last four quarters sum to roughly $6.51B, so the business is still growing around low-double digits. But net income went the wrong way. Excluding the obviously distorted 2024 quarter with $3.07B of income on $1.35B of revenue, annual net income was $1.07B in 2025 versus $1.40B in 2023 and $1.52B in 2022. Quarterly margins show the same compression: 27.8% in 4Q24, 25.3% in 1Q25, 21.7% in 2Q25, 18.7% in 3Q25, then a collapse to 5.8% in 4Q25, followed by only a partial recovery to 23.1% and 13.9% in the first two quarters of 2026. That is not the profile I want to pay nearly 50x earnings, 8.8x sales, and 35x EV/EBITDA for.
What stands out most is that the income statement is telling a harsher story than the cash flow statement. Free cash flow of $1.34B in 2025 against $1.07B of net income is fine, and the balance sheet is excellent with $2.94B of cash against just $598M of debt. This is absolutely not a balance-sheet problem. But the market cap is $52.3B, so the stock trades around 39x trailing FCF as well. For a company with annual revenue CAGR of roughly 0.5% over 2021-2025 and declining earnings over that span, that multiple already assumes the current margin dip is temporary and that growth re-accelerates enough to justify a structurally premium multiple. The quarterly revenue trend is respectable — from $1.35B in 3Q24 to $1.74B in 2Q26 is solid progress — but not extraordinary enough to carry this valuation on revenue growth alone. If this were a 30% grower with stable margins, maybe. It isn’t.
The mature-earner label is closer to the truth than the “platform monopoly” aura implied by the stock price. Gross margin remains superb at 78.0%, operating margin still sits above 20% on the annual print, and ROIC of 13.1% says this is a strong medical device franchise, not a broken one. But strong business does not equal attractive stock at any price. When a company with 2025 operating income of $1.26B and net income of $1.07B commands a $52B equity value, investors are underwriting a return to cleaner 25%+ net margins and a much longer runway than the recent reported earnings justify. I don’t see enough evidence in these numbers that this normalization is already earned. The market seems to be looking through the margin volatility as if it is transient; I think that is too generous until the company proves otherwise for several quarters in a row.
The best argument against this bear read is straightforward: the P/E looks artificially high because earnings are temporarily depressed, while the underlying franchise is still compounding. Revenue over the last five reported quarters rose from $1.41B to $1.74B, about 23% in absolute terms, and the latest quarter was up 11.6% year over year. If that continues while margins recover from the unusual 4Q25 trough, earnings power could snap back meaningfully. On normalized earnings, the stock may not be 50x at all. The company also has the kind of financial profile that deserves a premium versus diversified med-tech peers: net cash, high gross margins, current ratio of 3.7, and consistent positive FCF. A smart bull would also point out that the 2024 annual net income of $4.17B is clearly non-comparable because of a one-time benefit, so using headline earnings trends mechanically can mislead. I agree with that, which is why my issue is not that Edwards is deteriorating irreparably; it is that even after adjusting for noisy accounting, the current quote still discounts a very favorable recovery path.
What would change my mind is not another story about category leadership; it is a sequence of cleaner numbers. If Edwards can sustain revenue above $1.75B per quarter while restoring net margin back into the 20%-25% range for at least two to three consecutive quarters, then annualized earnings power moves closer to $1.4B-$1.7B and the premium multiple becomes easier to defend. I would also want to see 2026 revenue run-rate clear $6.8B with operating leverage, not just top-line growth bought with lower profitability. Absent that, I think the stock should trade more like a high-quality but maturing device leader — something closer to 25-30x normalized earnings or roughly 6x sales, which points to a value materially below today’s price, closer to the $60-$70 range than $90+.
Grok Reading
Edwards Lifesciences at $90.83 is a high-quality franchise being priced as if it still owns a growth monopoly it no longer demonstrates in the numbers. Annual revenue has gone nowhere meaningful: $5.23B in 2021, $5.38B in 2022, $6.00B in 2023, a dip to $5.44B in 2024, then $6.07B in 2025 — a 0.5% revenue CAGR that is essentially flat. Operating income has marched the wrong direction, from $1.69B–$1.75B in 2021–22 down to $1.53B in 2023, $1.38B in 2024, and $1.26B in 2025. The 2024 net income spike to $4.17B was almost entirely a one-time event visible in the September 2024 quarter’s $3.07B NI and 227% margin; strip that out and you have a business generating roughly $1.0–1.5B of ordinary earnings on a $52B market cap. Trailing PE of 49.6x, EV/EBITDA of 35.2x, and 8.8x sales sit on top of an ROE of 10.4% and ROIC of 13.1% — returns that do not justify a scarcity multiple. Free cash flow of $1.34B is real and the balance sheet is fortress-like ($2.94B cash against $598M debt, D/E 0.06), but the market is embedding the Thesis Evaluation’s implied 56% annual FCF compounding to ~$11B by 2030, a trajectory with zero support in the trailing data.
Recent quarters show a modest re-acceleration — revenue climbing from $1.41B in Q1 2025 to $1.74B in Q2 2026, with recent YoY revenue growth at 11.6% — yet profitability is not coming along for the ride. Net margin collapsed from the mid-20s into 13.9% in the most recent quarter and 5.8% in Q4 2025; operating leverage is deteriorating even as top-line ticks up. That pattern is consistent with a mature TAVR franchise facing share pressure and a TMTT ramp that is still spending, not yet earning. Gross margin remains elite at 78%, confirming procedural pricing power and product quality, but the conversion of that gross profit into operating profit and net income has been eroding for four years. The valuation synthesis fair value near $32 is aggressive on the downside, yet even a more charitable 25x on clean ~$1.1–1.2B earnings power lands in the mid-$50s — still a large gap to $91. The narrative layer is doing the heavy lifting: a platform-monopoly story about SAPIEN durability and demographic inevitability that the actual growth rates have stopped validating.
The strongest counter-case is straightforward. Edwards still prints $1.6B of operating cash flow with only $260M of capex, sits on a pristine net-cash balance sheet, and retains clinical standard-of-care status in TAVR with a multi-year international penetration runway and a TMTT pipeline that could re-rate the growth algorithm if mitral and tricuspid therapies scale. Sell-side and cardiologist narratives remain intact, recent 11–12% revenue growth could be the early innings of that re-acceleration, and a 78% gross margin business with switching costs this high rarely stays cheap for long once volume inflects. A bull can argue the 2024–25 earnings noise and temporary margin compression mask a still-dominant franchise that deserves a premium to diversified device peers. I weigh that less heavily because the premium already on offer is not a peer premium — it is a hyper-growth premium layered on top of a 0.5% five-year revenue CAGR, declining operating profit, and visible competitive entry from Boston Scientific and Abbott. High FCF quality and a clean balance sheet reduce downside to solvency risk; they do not justify paying 50x earnings for mid-single-digit normalized growth.
I would flip toward fair value or undervalued if the company posts three consecutive quarters of ≥12% organic revenue growth with operating margin stabilizing above 22%, or if TMTT revenue becomes large enough and accretive enough to lift group FCF growth into the mid-teens on a sustained basis. A clean re-acceleration of operating income back through $1.5B+ with the multiple still elevated would also force a re-rating of the thesis. Absent that evidence, the $90 handle remains a narrative multiple on a mature earner.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Edwards Lifesciences shows the hallmarks of a durable mature earner: 78% gross margins in 2025, $4.23B liquid cash against $3.63B net cash, an Altman Z of 11.97 (deep safe zone), and a Beneish M of -2.61 indicating no manipulation flags. The company is a net buyer of its own stock with diluted shares shrinking from 631M in 2021 to 586M in 2025 (-1.9% CAGR) and buybacks running 7.4x SBC, so per-share value is genuinely being concentrated rather than diluted. Revenue grew from $5.23B (2021) to $6.07B (2025), a modest ~3% CAGR that reflects the 2023 Critical Care divestiture noise (2024 revenue dip to $5.44B and the $4.17B net income that year likely reflects a divestiture gain). The concern is margin trajectory: operating margin has slid from 32.5% (2022) to 25.5% (2023) to 20.8% (2025) even as gross margin held at 78-80%. That is a ~1200bp operating margin compression in three years, pointing to opex growth (R&D/SG&A) outrunning revenue — either heavy investment in TAVR/TMTT pipeline or genuine operating deleverage. OCF/NI at 0.84x and the noted 'Weak Cash Flow Quality' also deserves scrutiny; 2024 FCF collapsed to $290M before rebounding to $1.34B in 2025, so cash conversion is lumpy. Insider activity is neutral-to-mildly negative (only sales, no opens buys, but small dollar amounts consistent with routine comp monetization).
Verify before trusting this (5)
- Cause of operating margin decline from 32.5% to 20.8% — is it R&D investment in TMTT/pipeline (bullish for durability) or SG&A creep and pricing erosion (bearish)?
- Nature of 2024 $4.17B net income spike — confirm Critical Care divestiture gain and whether 2025 $1.07B net income is the clean run-rate.
- Working capital drivers behind 2024 FCF collapse to $290M and 2025 rebound to $1.34B — is cash conversion structurally weakening or just timing?
- Organic revenue growth ex-divestitures — is core TAVR/TMTT growth accelerating or is competition (Abbott, Medtronic) compressing share?
- Segment concentration: what % of revenue and profit is TAVR alone, and what is the competitive threat pipeline?
The e2e synthesis pins composite FV at $31.26 and signal-adjusted FV at $32.13, implying roughly -65% downside from $90.81. Even the most generous method, anchored PE at $44.99, still sits ~50% below the current price. All three methods (DCF $26.21, EPV $27.63, anchored PE $44.99) agree the market is paying a substantial premium to any defensible intrinsic anchor. I do think the composite understates deserved value for a Strong-quality franchise with real TAVR moat, so I would not take -65% literally, but the direction is unambiguous. Adjusting upward for franchise quality and giving generous credit to the platform, I get to a deserved value in the $55-70 range, still well below $90.81. What is priced in: mid-teens revenue growth for a decade, stable-to-expanding margins despite the 32.5% to 20.8% operating margin compression already visible, and no meaningful share loss to Boston Scientific or Abbott. That is a demanding stack of assumptions with zero cushion. Margin of safety is negative. This is a good business at a full-to-rich price - the classic setup where the quality lens says 'keep watching' and the valuation lens says 'not here.'
Verify before trusting this (5)
- TAVR volume growth trajectory and pricing in latest guidance vs consensus
- Competitive share data for Boston Scientific ACURATE neo2 and Abbott Navitor
- Operating margin trajectory - is the 20.8% a trough or new normal
- R&D and SG&A intensity going forward - management commentary on reinvestment cycle
- Any one-off items depressing recent FCF conversion
The macro backdrop is mildly supportive: risk-on regime at +44, VIX subdued at 15.2, and no macro cross-current hitting medtech specifically. With a beta of 0.85, EW absorbs less of the tape either way, so the market-wide risk-on push lands as a light, not decisive, tailwind on this name. Recent momentum is meaningfully positive (11.6% recent vs 0.5% long-term), suggesting money is flowing back into the story after a period of drift. The narrative remains the dominant force: EW is still framed as a platform-monopoly in TAVR with strong intensity and medium cult coefficient, which anchors sentiment on the bull side. But durability is only moderate and the bear thread is live and coherent - decelerating TAVR growth, Boston Scientific and Abbott encroachment - which caps how far the tailwind can run. There is no fresh negative catalyst in the news flow (the BD headline is unrelated), and no analyst tone shift flagged, so nothing is actively pressing the stock lower right now. Net read: a real but ordinary tailwind, not a euphoric one.
Verify before trusting this (4)
- Any Q3 TAVR volume or market-share data suggesting Boston Scientific or Abbott gains
- Analyst target revisions or downgrades citing competitive erosion
- Sector rotation out of defensive medtech if the risk-on tape accelerates into cyclicals
- A CMS or reimbursement headline that could crack the monopoly framing
Edwards sells a physical implant placed by a trained interventionalist under regulatory and liability constraint, so AI cannot substitute the product or the procedure; the transmission runs almost entirely through the demand funnel and the cost of evidence generation. On the demand side, algorithmic echo interpretation and EHR phenotyping attack the documented undertreatment gap that caps TAVR/TTVR TAM — a volume tailwind Edwards captures without changing its monetized unit (per-valve ASP). On the supply side, AI compresses trial simulation, imaging-based patient selection and regulatory documentation cost, relevant given operating margin has fallen from 32% to 21% on mitral/tricuspid investment. Against that, AI already sits inside the hemodynamic monitoring franchise (predictive hypotension algorithms), which is the one line where software-native entrants could commoditize the value; and payer-side AI is a genuine, underappreciated brake on reimbursed procedure counts. Net: modest positive, low magnitude, and the finding is that exposure is low rather than that AI transforms the business.
None surfaced.
Verify before trusting this (8)
- Elderly population procedure penetration rates
- Untreated severe AS prevalence studies
- Guideline expansion to asymptomatic patients
- TAVR average selling price by region
- Bundled payment/DRG reimbursement changes
- Volume growth vs price mix disclosure
- Pharmacologic AS therapy trial readouts
- Durability data on bioprosthetic valves
The demand substrate here is demographic and largely macro-immune: severe valve disease prevalence tracks the over-70 population, and the procedure is life-extending rather than discretionary, so a 4.68% ten-year and a neutral macro backdrop barely touch volumes. What is changing in the world around Edwards is clinical, not economic — the standard of care is migrating from surgery to catheter-based intervention and, within that, from symptomatic late-stage patients to earlier intervention, while mitral and tricuspid disease follows the same path aortic did a decade ago. That migration is the growth. The offsetting world force is that transcatheter structural heart is no longer a one-firm frontier: every large-cap device peer now treats it as a priority franchise, and health systems face staffing and cath-lab throughput limits that meter how fast an expanded indication becomes billed procedures. Net: a durable, demographically-underwritten mid-teens-fading-to-low-double-digit grower in a growing category — a good business direction, and a completely different question from whether 56% compounding is achievable.
When we made this prediction on Aug 18, 2026, EW was $90.81. We expect it to be $83.50 by Feb 2027, and we consider it great value under $60.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 18, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.